Coverage of the EASD meeting highlights a shift in obesity care toward body composition, featuring the Phase 2 COURAGE trial and new cardiometabolic guidance.
On October 3, 2026, ConscienHealth published coverage of the European Association for the Study of Diabetes meeting. This major scientific meeting took place in Milan from September 28 to October 2, 2026. The reporting framed the event as a snapshot of a rapidly changing obesity-treatment landscape. Researchers are shifting their focus from simple scale weight toward body composition and overall cardiometabolic health.
The coverage portrays obesity-treatment evaluation as broadening significantly across the medical community. It now includes muscle and bone health, liver and visceral fat, and cardiovascular protection. Kidney protection, appetite regulation, and diabetes control are also central to the modern discussion. This comprehensive view marks a departure from older, more restrictive treatment models.
A central story from the meeting was the Phase 2 COURAGE trial. This trial evaluated trevogrumab alongside semaglutide in people with obesity. Trevogrumab is currently an investigational antibody. Researchers designed the trial to test if this combination could change how weight is lost over time.
ConscienHealth described the new EASD and ADA consensus presented at the meeting. This guidance recognizes the growing concern about lean-mass loss during active weight reduction. It also emphasizes the importance of resistance exercise for patients taking medication. Medical professionals are increasingly placing GLP therapies within a broader cardiometabolic framework.
These discussions highlight a critical shift in how we view metabolic health. The conversation is moving beyond the simple question of how much weight a person loses. Clinicians are now asking what kind of weight is lost during these treatments. Tolerability, persistence, and other health dimensions are becoming just as important as the number on the scale.
Trevogrumab functions by blocking a specific protein pathway in the human body. It is an investigational antibody that blocks GDF8, which is also known as myostatin. Myostatin naturally limits muscle growth to keep the body balanced. Researchers hypothesize that blocking this protein might help patients maintain muscle tissue while losing fat.
The Phase 2 COURAGE trial tested this mechanism by pairing trevogrumab with semaglutide. Semaglutide is a medication that reduces appetite and supports significant weight loss. The trial measured how the body changed over 52 weeks using two different imaging methods. This dual approach helps clarify the difference between overall lean mass and specific muscle volume.
The COURAGE results clearly distinguish DXA-measured lean mass from MRI-measured thigh muscle volume. DXA scans measure everything in the body that is not fat or bone. This means a DXA scan includes water weight and organ tissue in its lean mass calculation. An MRI provides a much more specific measure of actual muscle volume in a targeted area.
Understanding this distinction is vital for analyzing body composition and obesity medications program data. Lean mass and thigh muscle volume are related but not identical endpoints. An increase or preservation of lean mass does not perfectly equal an increase in skeletal muscle. The scientific community is still learning how these specific measurements interact during significant weight reduction.
At WeightRestart, our body-neutral approach focuses heavily on metabolic health and long-term habits. We know that maintaining functional lean mass is critical as human bodies age. When a patient loses weight rapidly, they typically shed a mix of fat, muscle, and water. Medical researchers are highly interested in finding safe ways to prioritize fat loss while protecting functional tissue.
Mainstream headlines about preserved muscle require careful qualification and context. Lean-mass and MRI muscle-volume changes are strictly body-composition measures. They are not proof of improved physical strength, daily mobility, or overall quality of life. The cited release from Regeneron does not report these long-term functional outcomes.
ConscienHealth strongly cautioned that the COURAGE findings do not guarantee better health. The trial data shows statistical preservation of tissue volume under medical imaging. However, this does not automatically prove that patients will experience better long-term function. It is entirely possible to preserve muscle mass without seeing proportional improvements in physical performance.
It is also important to remember the current regulatory status of these treatments. The COURAGE results come from a Phase 2 trial. Trevogrumab remains an investigational drug at this time. Regeneron explicitly states that its safety and efficacy have not yet been evaluated by any regulatory authority.
Our brand promise is to provide clear, research-led, and shame-free guidance. We believe in making uncertainty visible so you can make better-informed weight-management decisions. The uncertainty in the COURAGE trial is the gap between imaging results and actual physical health. Patients should understand that medical imaging is only one piece of the metabolic puzzle.
The COURAGE trial reported specific body composition changes over a 52-week lower-dose period. DXA-measured lean mass fell 7.3% with semaglutide plus a placebo. Lean mass fell 5.8% with 25 mg trevogrumab and 4.2% with 75 mg trevogrumab. Regeneron calculated a relative lean-mass preservation of 20.5% and 42.5% for the two trevogrumab doses.
The study also included an MRI substudy to look closer at muscle volume. The 75 mg dose was associated with 68.9% preservation of thigh muscle volume at 52 weeks. This was compared directly to the semaglutide plus placebo group. The reported MRI results apply only to participants with evaluable scans, and the source does not state their exact number.
The trial also recorded important safety and tolerability data over the active period. Regeneron reported at least one adverse event in 77% of participants receiving lower-dose trevogrumab. This compared to 82% of participants who received a placebo during the trial. The most common events occurring in at least 10% of patients included nausea, constipation, diarrhea, and vomiting.
ConscienHealth also highlighted other notable obesity-treatment results from the EASD meeting. Lilly’s EloraTZP combination was reported to produce average weight loss of 23.3% at 48 weeks. This occurred in people with obesity and type 2 diabetes. This compared with a 14.8% weight loss for tirzepatide alone in a similar timeframe.
These findings align with ongoing efforts to understand how EloraTZP performs in clinical populations. ConscienHealth noted that gastrointestinal tolerability and discontinuation were concerns in some combination groups. The coverage also reported up to 20.8% weight loss at 80 weeks with retatrutide in people with obesity and diabetes. Zealand Pharma’s amylin agonist petrelintide showed up to about 10.7% weight loss.
These figures are summarized findings from the coverage and are not interchangeable head-to-head comparisons. The separate higher-dose portion of COURAGE tested trevogrumab with semaglutide for 26 weeks. Patients then continued trevogrumab or a placebo after the semaglutide was discontinued. This complex trial design highlights the ongoing search for effective maintenance strategies after initial medical intervention.
Regeneron says it plans a new Phase 2 study of trevogrumab with GLP-1-based therapies. This upcoming trial will focus on older adults with obesity and decreased muscle mass or strength. The company did not provide a start date or planned trial size in the cited release. This planned follow-up suggests an intent to study muscle preservation in a particularly vulnerable group.
The available coverage describes resistance exercise as an important part of the consensus discussion. However, the reports do not provide a detailed exercise prescription for patients. There is also no evidence that a particular training program was formally tested in the COURAGE trial. This lack of specificity leaves questions about how exercise interacts with these investigational medications.
This highlights a growing need to clearly define the role of physical activity during obesity treatment. Future research must establish whether investigational body composition changes actually improve physical function. We need more data to understand if preserving muscle volume directly leads to better metabolic health. Until then, body composition and overall cardiometabolic health deserve careful attention alongside traditional weight change.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
